StockDrifts LogoStockDrifts

SL Therapeutics 258540

Company
에스엘테라퓨틱스SL Therapeutics
Insiders
1
Buys
0
Total Value
₩4M ($2K)
Avg Return
+93.55%
Last Filing
2024-06-13

SL Therapeutics (258540) has 0 disclosed insider purchases and 1 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩4M ($2K) in reported transaction value. The earliest filing StockDrifts holds for SL Therapeutics is dated 2024-06-13; the most recent is 2024-06-13. Across these filings the average return since disclosure is +93.55%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2024-06-13SELLMarket Sell
에스엠비투자파트너스
SMB Investment Partners
--2.0K₩1,784+93.5%₩4M ($2K)

Frequently asked questions

Who has been buying SL Therapeutics stock?
1 distinct insiders have filed 0 disclosed insider purchases in SL Therapeutics (258540), most recently on 2024-06-13. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does SL Therapeutics have?
SL Therapeutics has 0 buy-side and 1 sell-side disclosures on record, covering ₩4M ($2K) in total reported value, spanning 2024-06-13 to 2024-06-13.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.